Revenue
2019
2020
2021
2022
2023
2024
2025
Universe Pharmaceuticals INC (UPC)
Price$4.20Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $17.86B | $23.02B | $32.3M | $40.1M | $48.0M | $30.7M | $33.2M |
| Gross profit | $6.30B | $6.07B | $10.3M | $21.9M | $25.3M | $14.1M | $13.4M |
| Gross margin | 35.28% | 26.37% | 31.93% | 54.53% | 52.78% | 45.90% | 40.35% |
| Research & development | $671.8M | $3.03B | $4.9M | $7.6M | $5.5M | $583,125 | $618,437 |
| Operating expenses | $9.22B | $14.09B | $14.3M | $28.9M | $11.7M | $3.8M | $3.7M |
| Operating income | −$2.92B | −$8.02B | −$4.0M | −$7.0M | $13.6M | $10.3M | $9.8M |
| Operating margin | −16.33% | −34.83% | −12.28% | −17.49% | 28.32% | 33.39% | 29.35% |
| EBITDA | −$2.40B | −$7.53B | −$3.5M | −$6.5M | $14.0M | $10.7M | $10.2M |
| EBITDA margin | −13.43% | −32.72% | −10.70% | −16.16% | 29.25% | 34.72% | 30.61% |
| Net income | −$3.67B | −$8.73B | −$6.6M | −$7.9M | $11.3M | $7.6M | $7.6M |
| Net profit margin | −20.56% | −37.90% | −20.37% | −19.70% | 23.59% | 24.62% | 22.73% |
| Basic EPSper basic share | -$8.06 | -$626.96 | -$1.09 | -$1.31 | $3.58 | $2.82 | $2.82 |
| Diluted EPSper diluted share | -$8.06 | -$626.96 | -$1.09 | -$1.31 | $3.58 | $2.82 | $2.82 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
HRT FINANCIAL LP | 16.9K |
UBS Group AG | 14.37K |
OSAIC HOLDINGS, INC. | 6.17K |
Caitong International Asset Management Co., Ltd | 12 |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data